Skip to main content
Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc. — Investor Relations & Filings

Ticker · ATXS ISIN · US04635X1028 US Manufacturing
Open in API
Filings indexed 602 across all filing types
Latest filing 2026-01-23 Director's Dealing
Country US United States of America
Listing US ATXS

About Astria Therapeutics, Inc.

https://astriatx.com/

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for allergic and immunologic diseases. The company's mission is to provide life-changing treatments to patients and their families. Its lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein being developed as a potential long-acting, preventative treatment for Hereditary Angioedema (HAE). The company has reported positive initial proof-of-concept results from its ALPHA-STAR Phase 1b/2 clinical trial for STAR-0215. Astria Therapeutics is guided by patient needs to develop differentiated therapeutics that address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2026-01-23 English
S-8 POS Filing
Regulatory Filings
2026-01-23 English
8-K Filing
Regulatory Filings
2026-01-21 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by Astria Therapeutics, Inc. It reports on a merger agreement with BioCryst Pharmaceuticals, including references to a definitive proxy statement related to the merger and legal complaints filed against the company and its board. The document includes forward-looking statements caution and detailed information about where to find the proxy statement and registration statement. The content focuses on merger-related disclosures and legal proceedings rather than financial results or management discussion. The document is not a full annual or quarterly report, nor is it a proxy solicitation itself but references the proxy statement. It is a current report on Form 8-K, which is a regulatory filing used to disclose material events. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like M&A filings or legal proceedings report, since it primarily reports the event and references other filings rather than being the merger filing or legal report itself.
2025-12-23 English
425 Filing
Regulatory Filings
2025-12-23 English
DEFM14A Filing
Regulatory Filings
2025-12-18 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.